Stay updated with breaking news from Broadwing Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sanofi is acquiring rights to a Maze Therapeutics drug candidate for Pompe disease that could give the pharmaceutical giant another option to offer patients who have the rare metabolic disorder. In February, the drug posted positive data from a Phase 1 study.
Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.
In a cross-sectional study, Michael Wainberg and colleagues investigate the association between accelerometer-derived sleep measures and lifetime psychiatric diagnoses.